Angiotensin-Neprilysin Inhibition as a Paradigm for All?

Muthiah Vaduganathan; Akshay S. Desai

doi:https://doi.org/10.1007/s11886-016-0784-z

doi.org/10.1007/s11886-016-0784-z

Angiotensin-Neprilysin Inhibition as a Paradigm for All?

,

Current Cardiology Reports3.70

Volume: 18, Issue: 11

Published: Oct 17, 2016

Abstract

Composite angiotensin receptor-neprilysin inhibition (ARNi) represents a novel pharmacologic strategy for treatment of heart failure with reduced ejection fraction (HFrEF). In the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial of 8399 subjects with HFrEF, treatment with the ARNi LCZ696 (sacubitril/valsartan) was associated with statistically important reductions...